Search Results

Pharmacology & Therapeutics   2016 , 165 , 164–177. https://doi.org/10.1016/j.pharmthera.2016.06.007 European Journal of Pharmacology   2017 , 799 , 58–66. https://doi.org/10.1016/j.ejphar.2017.01.040 . European Journal of Pharmacology   2018 , 839 , 40–46. https://doi.org/10.1016/j.ejphar.2018.09.008 . Trends in Pharmacological Sciences   2018 , 39  (2), 187–199. https://doi.org/10.1016/j.tips.2017.10.004 Biochemical Pharmacology   1973 , 22 (23), 3099–3108. https://doi.org/10.1016/0006-2952(73)90196-2 .

GPCR Enthusiasts , Get ready for an exciting learning experience with our newly updated Principles of Pharmacology New Course Dates: Principles of Pharmacology I :  October 3, 10, 17, 24 (four sessions) Principles of Pharmacology II :  October 31, November 7, 14, 21, December 5 (five sessions) Courses Highlights Act Fast: Don’t miss this incredible opportunity to immerse yourself in the  Principles of Pharmacology and ' Advanced Data Analysis for GPCR Pharmacology' ."

detailed structure‐activity relationship that identifies small changes to the ligands that invert their pharmacological

Every R&D team is under the same pressure: deliver validated targets, clean pharmacology, and translatable Allosteric Interactions Still Matter Orthosteric and allosteric interactions have been in pharmacology learn why this distinction is not just theory, but a practical framework to design cleaner, smarter pharmacology Equip your team with this literacy now to design cleaner pharmacology and accelerate smarter, safer programs lectures  that sharpen the tools you actually use in discovery A growing on-demand library  of expert pharmacology

Exploit probe dependence to shape precision pharmacology.  Want to avoid off-target effects? If you work on GPCRs across translational pharmacology, drug development, or molecular pharmacology,

Congratulations to Andrew Tobin for an incredible week filled with prestigious events, including receiving the British Pharmacological Society Vane Medal and switching on the Christmas lights at the University of Glasgow and TPD Structural Biology Platforms GPCR Events, Meetings, and Webinars December 10 - 12, 2024 | Pharmacology | BIO International Convention 2025 July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology Research Associate - Professor Graeme Milligan Postdoc in Molecular Pharmacology - The Hauser Group

-dipolar cycloaddition), which is a very robust conjugation strategy to obtain linkers with a rigid moiety

Rather than treating opioid pharmacology as a purely theoretical exercise, she collaborates with harm-reduction This approach makes her models not just rigorous, but translational—bridging the gap between receptor pharmacology That personal loss transforms complex receptor pharmacology into something immediate and human. And GPCR pharmacology isn’t just an academic pursuit—it’s essential to understanding and responding to

Is Your GPCR Program Slowing Down—Even With Good Data? You’re not alone. Most teams don’t stall because the science is weak. They stall because the data becomes a mess. I call it the Lego Bucket Problem : You’ve got CRO output, internal assay data, maybe even some promising signals. But there’s no blueprint. No structure. No clear path to your next milestone. Meetings drag. Decisions stall. And momentum quietly dies. The Hidden Cost of Good Science Without Systems I’ve seen this pattern again and again—across academia, biotech, and through close work with dozens of teams inside the Dr. GPCR Ecosystem. Strong science. Promising data. But no systems to turn it into momentum. Data arrives too fast and too fragmented CROs deliver output without clear integration Teams chase the wrong assays, too late to pivot Milestones slip—and nobody realizes until it’s too late Failing fast? Not possible when nothing’s built to surface the right  insights early. That’s Why I Built Yamina’s Consulting Corner This is not “advising.” This is embedded consulting for biotech and VC teams who need to move fast —without compromising scientific integrity. Unlike traditional advisors, I'm not just observing; I'm part of your team . This allows me to experience your challenges firsthand, identify roadblocks faster , and i mplement solutions from within , ensuring genuine buy-in and lasting momentum. Here’s what I bring: Biology-First Strategy I’ve designed GPCR assays, led collaborations across research environments, and translated complex data into action. I know how to ask the right scientific questions—and when to shift from analysis to execution. Systems That Drive Execution No more disconnected slides and 6-week meeting cycles. I install simple tools that surface insights, align your team, and keep momentum moving. True Embedded Partnership I review CRO scopes, flag risks early, and sit in on your strategic calls. I’m not watching from the sidelines—I’m driving with you. Real-Time Global Insight As founder of Dr. GPCR, I’m connected to 1,300+ scientists and decision-makers worldwide. That network gives me a constant pulse on what’s working—and what’s next. Who I Work With ✅ Biotech Teams  – Especially those lacking in-house GPCR leads or overwhelmed by CRO data chaos. ✅ Venture Capital Firms  – Looking to accelerate, troubleshoot, or validate GPCR assets in their portfolio. ✅ Contract Research Organizations (CROs)  – Wanting to better align with biotech clients and deliver real  insight, not just data. My Consulting Philosophy Every successful GPCR program is a blend of scientific excellence  and operational precision . One without the other will quietly kill your momentum. My work is rooted in: ✔️ Scientific Integrity ✔️ Operational Discipline ✔️ Collaborative Partnership Let’s Get Your GPCR Program Moving Again Whether you’re building from scratch or recovering from a stall, I’ll help you move faster—with fewer blind spots, tighter execution, and a clear line of sight to your next key decision. 🚀 Book your free 30-minute strategy call Let’s unlock the momentum your GPCR program needs. 👉 https://calendly.com/drgpcr/yamina-corner Or explore how we can work together: 👉 Yamina.org 🔑 Key Takeaways ✅ Even strong science stalls without operational structure ✅ Scattered data = missed insights = wasted time ✅ You can’t fail fas t if you can’t see the problems early ✅ Most teams don’t need more data— they need clarity ✅ Yamina’s Corner helps teams move from data chaos to decisive action ✅ This is hands-on support —not passive advising p.s: Still unsure if this is the right fit? Let’s talk through your program—no pitch, just clarity.

August 2022 Dopamine D 1 receptor-mediated β-arrestin signaling: Insight from pharmacology, biology, We now summarize important pharmacological, molecular, and cellular studies relevant to D1-mediated β-arrestin-related

Corner , our founder Yamina Berchiche works closely with organizations to help them navigate receptor pharmacology Push the boundaries  of receptor pharmacology and its real-world applications.   📚 Terry’s Corner — The Only On-Demand Pharmacology Hub with Dr. GPCR  community, you already know about Terry’s Corner  — our exclusive, on-demand pharmacology series where Terry Kenakin breaks down receptor pharmacology, functional selectivity, and ligand bias in a

It’s rigorous pharmacology, but deeply tied to urgent public health needs.

August 2022 A NanoBRET-Based H 3 R Conformational Biosensor to Study Real-Time H 3 Receptor Pharmacology monitor the activation state of G protein-coupled receptors are a useful addition to the molecular pharmacology evaluating its compatibility with photopharmacological ligands that contain a light-sensitive azobenzene moiety

First responders describe revivals that don’t feel like revivals, as if the body is still trapped in a pharmacological

Yet some assumptions still shaping pharmacology workflows haven’t evolved as fast as today’s science. Unlock “Rethinking Affinity” Now Only in Terry's Corner _____ #GPCR #BindingAffinity #Pharmacology

’s Highlights: Congratulations to our amazing Board Member JoAnn Trejo for being elected to the British Pharmacological Society Honorary Fellowship! | BIO International Convention 2025 July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology Principal Scientist, Medicinal Chemistry PhD fellowship in GPCR mechanosensing Senior Scientist, GPCR Pharmacology Research Associate - Professor Graeme Milligan Postdoc in Molecular Pharmacology - The Hauser Group

Rethinking Affinity, A Critical Edge for Drug Hunters One of the most persistent misconceptions in pharmacology apparent affinity differences delays key milestones. 🗣️ “Thank you for bringing this (Principles of Pharmacology At Alkermes, Sokhom Pin built an in vitro pharmacology group from scratch—not just a lab, but a culture Weekly News : jobs, events, papers, industry updates Exclusive discounts on Terry’s Corner  digital pharmacology Access this week’s full Premium Edition here ➤ Hashtags: #GPCR #DrGPCR #BindingAffinity #Pharmacology

Molecular innovation This Week’s GPCR Intelligence: The next edge in discovery isn’t louder exposure—it’s smarter engagement. This week’s Dr. Kenakin from Terry's Corner shows how to tame irreversible drugs so their kinetic power works for you, not against you. You’ll get a framework to predict duration, penetration, and PK/PD separation—so decisions move faster and risks surface earlier. Breakthroughs this week:  nanomedicines targeting PAR2 for sustained analgesia; Emerging Voices in GPCR Biology; Domain Therapeutics patents new PAR2 antagonists. 🔍 This Week in Dr. GPCR Premium: Sneak Peek Industry insights:  Confo VLAIO grant; Skye CB1 Ph2 miss; Chugai CT-388 in-license; Septerna valuation. Upcoming events:  Membrane-mimetic screening; GPCR Forum 2025; GPCR-TDD Summit Europe. Career opportunities:  Sr. Scientist—In-vitro Pharm; Postdoc roles. Must-read publications:  AT1R β-arrestin bias; UII receptor structure; β2AR constant-pH dynamics. Terry's Corner – Control Target Engagement—Don’t Chase It with Irreversible Drugs When binding outlives exposure, everything changes. This feature frames how to define “irreversible” in real systems, anticipate PK/PD separation, and use target turnover to tune duration. You’ll see why tight binding can backfire on tissue penetration, where k_inact/K_I beats classic Ki, and how to quantify what matters—speed of inactivation and durability of effect. If your team is designing covalent or tight-binding candidates, these principles reduce surprises and accelerate dose optimization. You’ll avoid costly missteps by: Preventing kinetic traps —spot PK/PD decoupling early so washouts and C_max don’t mislead dosing strategy. Designing for penetration —balance on/off rates to reach inner tissue, not just peripheries. Quantifying what counts —prioritize k_inact and k_inact/K_I to compare irreversible inhibitors realistically. 🎥  Live AMA with Dr. Kenakin — October 30, 12 PM EST   Join Dr. Kenakin live and bring the questions that keep you thinking. Each AMA feeds directly into next month’s lessons—your real-world challenges shape what comes next.   Your Membership Gives You: Proven frameworks used in real discovery programs On-demand lessons built for tight research schedules A say in the topics covered next Weekly updates that keep your knowledge sharp Monthly live AMAs with Dr. Kenakin Trusted insights from biotech, pharma, and academia 🎬 Plus New: Lesson Trailers   Curious about Terry’s Corner before committing? Watch our new trailers for a preview of expert-led GPCR training designed for scientists and drug hunters.    💎  $2,999/year — the cost of one conference = a year of expert training — Premium Members Enjoy Over 50% Discount at Checkout Get Yearly Access On-Demand Now — Free 7 Day Trial ➤ DrGPCR Podcast: Jens Carlsson on Predictive Modeling Prediction over explanation—that’s the shift. Jens Carlsson shares how structure-based design, molecular dynamics, and smart collaboration turn models into decisions, with practical guardrails on AlphaFold’s limits. Ideal for scientists who want modeling to guide experiments, not just narrate them. Value at a glance: From screens to hits —how to identify novel GPCR ligands with structure-based workflows. Know the limits —where AI helps and where it still overpromises. Bridge the aisle —modelers × experimentalists for faster iteration. Listen to the episode ➤ Why Dr. GPCR Premium Membership Gives You an Edge Premium provides scientists with weekly expert lectures, industry updates, priority events, targeted roles, and editorial context, allowing proactive action before signals become headlines. It’s an operating system for discovery decisions, featuring practical frameworks, trusted curations, and a community that accelerates your progress. Staying current is essential as kinetics, structure, and signaling evolve rapidly. Premium keeps you oriented and out of avoidable dead-ends. FAQ 🔹 What’s included?   The complete Weekly News digest, curated jobs, upcoming events, classified GPCR publications, and on-demand expert frameworks—plus member-only discounts. 🔹 Who is it for?   GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need fast, curated, career-relevant intelligence. 🔹 Why now?   GPCR innovation is accelerating; act on the right signals today to shape tomorrow’s breakthroughs—and avoid delays others won’t see coming 👉 Already a Premium Member? Access this week’s full Premium Edition here ➤ What our members say "Thank you for bringing this course with Dr. Kenakin… sorely needed in the field." — DrGPCR University Attendee 🚀 Join now — and learn to design drugs that don’t just bind tighter, but work smarter and last longer. Become a Premium Member today. ➤ 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers & event intelligence 🤝 Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career stage

With limited structural data but a growing pharmacological interest, GPCRs presented the perfect challenge Pharmacology, on the other hand, is often outsourced through collaborations with expert labs who specialize Trainees must learn how to interpret assay data, understand pharmacological context, and communicate predictive modeling matures, its role will continue to expand, guiding ligand discovery, informing pharmacology

What started as hand-built assays on ice has become integrated platforms for drug discovery, systems pharmacology

β-receptor partial agonists, showing how heart rate set-points under different anesthetics can flip observed pharmacology Subscribe today and get direct access to decades of pharmacology experience that turn complex systems Why Terry’s Corner Most pharmacology training freezes at equilibrium snapshots.

From Cambridge to Leadership That early curiosity led her to pursue a PhD in Molecular Pharmacology at

When Curves Shift Some of the most difficult calls in pharmacology happen when two curves look  slightly Is it a real pharmacological effect, or just noise? Here’s where the F-test  becomes indispensable. engagement opportunities  through AMAs and topic suggestions Practical insights  distilled from decades of pharmacology curvecomparison #ftest #assayvalidation #experimentaldesignstatistics #assayreproducibility #ANCOVA #pharmacology

If your work touches GPCR pharmacology, these insights aren’t optional—they’re essential. Career opportunities:  Senior/Principal Scientist—GPCR Pharmacology; Principal Scientist—In Vitro Pharmacology Terry’s Corner: GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures Discovery collapses

Each week we highlight the decisions that move GPCR projects forward—from pharmacology essentials to Years of chemistry, photophysics, and pharmacology condensed into one breakthrough: pHSense , a reagent They translated a fundamental principle of chemistry into a usable platform for pharmacology—showing

Schild analysis turns receptor pharmacology into detective work, spotlighting mechanistic fingerprints Modern pharmacology has powerful modeling software, yet Schild analysis remains the litmus test for mechanism Watch the course trailer 👇 Why Terry’s Corner Weekly pharmacology lectures by Dr.

GPCR internalization isn’t just a trafficking readout—it’s pharmacology. s partnership with Durham (chemistry) and the Institute of Functional Genomics in Montpellier (GPCR pharmacology

research position in GPCR biochemistry and biophysics and a research associate/scientist in in vitro pharmacology “The best pharmacology teacher (Dr. Also super-valuable for those of us learning how to teach pharmacology” — Dr.

Pharmacological chaperones are cell-permeant small molecules that engage nascent mutant GPCRs in the Therefore, CAN1404 acts as a pharmacological chaperone and can rescue cell surface expression and function effects of genetic mutations on GPCR function and provide a proof of therapeutic principle for FSHR pharmacological

members — Susanna Naggie, MD, and Sudarshan Rajagopal, MD, PhD — have been elected to the American Society Naggie and Rajagopal are two of 95 new members elected to the society for 2022.